重组人促红细胞生成素联合铁剂治疗围手术期贫血

Combined Therapy of Recombinant Human Erythropoietin and Iron Complex for Perioperative Anemia

重组人促红细胞生成素(促红素)与铁剂联合治疗方案的长期应用,已被证实对肾性贫血或肿瘤相关性贫血具有良好疗效。然而,对于围手术期贫血的短期治疗,联合应用的证据尚不充分。相比于促红素单药治疗,联合治疗从不同角度升高血红蛋白,从而叠加贫血治疗效果,缩短疗程,提高治疗效率。我们开展了一项回顾性病例对照研究,纳入95例骨科围手术期轻度贫血(血红蛋白≥90 g·L-1)患者,结果发现联用组术后血红蛋白水平显著高于单用组,而术后输血风险约为单用组的25%,提示对于围手术期轻度贫血患者,联合治疗可能优于单药治疗。

Combined therapy of recombinant human erythropoietin（EPO） and iron complex has been proved to be efficient for renal anemia and cancer-related anemia in long-term. However, the evidence for short-term treatment of perioperative anemia is limited. Compared with EPO alone, combined therapy may promote hemoglobin rise through different approaches and improve the treatment efficiency. We employed a retrospective case-control study involving 95 patients with mild perioperative anemia（hemoglobin ≥90 g·L-1）from orthopedics department. We found that the hemoglobin levels of patients receiving combined therapy were significantly higher than those in EPO alone group. The transfusion risk in the combination group was about 25% of that in the EPO alone group. This study implied that combined therapy might be better than EPO alone for perioperative anemia.